Export 21 results:
Author Title Type [ Year(Desc)]
Filters: Author is Dally, Len  [Clear All Filters]
2010
S. Vasan, Schlesinger, S. J., Chen, Z., Hurley, A., Lombardo, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Boente-Carrera, M., Schmidt, C., Fang, Q., Huang, Y., Zaharatos, G. J., Gardiner, D. F., Caskey, M., Seamons, L., Ho, M., Dally, L., Smith, C., Cox, J., Gill, D., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine., PLoS One, vol. 5, no. 1, p. e8816, 2010.
S. Vasan, Schlesinger, S. J., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D. K., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine., PLoS One, vol. 5, no. 1, p. e8617, 2010.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E. M., Graham, B. S., Koup, R. A., Bailer, R. T., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C. M., Bizimana, J., Tarragona-Fiol, T., Bergin, P. J., Hayes, P., Ho, M., Loughran, K., Komaroff, W., Stevens, G., Thomson, H., Boaz, M. J., Cox, J. H., Schmidt, C., Gilmour, J., Nabel, G. J., Fast, P., and Bwayo, J., Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa., PLoS One, vol. 5, no. 9, p. e12873, 2010.
A. Spentzou, Bergin, P., Gill, D., Cheeseman, H., Ashraf, A., Kaltsidis, H., Cashin-Cox, M., Anjarwalla, I., Steel, A., Higgs, C., Pozniak, A., Piechocka-Trocha, A., Wong, J., Anzala, O., Karita, E., Dally, L., Gotch, F., Walker, B., Gilmour, J., and Hayes, P., Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates., J Infect Dis, vol. 201, no. 5, pp. 720-9, 2010.
2016
G. Mutua, Farah, B., Langat, R., Indangasi, J., Ogola, S., Onsembe, B., Kopycinski, J. T., Hayes, P., Borthwick, N. J., Ashraf, A., Dally, L., Barin, B., Tillander, A., Gilmour, J., De Bont, J., Crook, A., Hannaman, D., Cox, J. H., Anzala, O., Fast, P. E., Reilly, M., Chinyenze, K., Jaoko, W., Hanke, T., and Group, T. Hiv- Core 0, Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults., Mol Ther Methods Clin Dev, vol. 3, p. 16061, 2016.
S. Chakraborty, Harro, C., DeNearing, B., Bream, J., Bauers, N., Dally, L., Flores, J., Van de Verg, L., Sack, D. A., and Walker, R., Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects., Clin Vaccine Immunol, vol. 23, no. 4, pp. 315-25, 2016.
M. D. Tapia, Sow, S. O., Lyke, K. E., Haidara, F. Cheick, Diallo, F., Doumbia, M., Traore, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., Sztein, M. B., Wahid, R., Campbell, J. D., Kieny, M. - P., Moorthy, V., Imoukhuede, E. B., Rampling, T., Roman, F., De Ryck, I., Bellamy, A. R., Dally, L., Mbaya, O. Tshiani, Ploquin, A., Zhou, Y., Stanley, D. A., Bailer, R., Koup, R. A., Roederer, M., Ledgerwood, J., Hill, A. V. S., W Ballou, R., Sullivan, N., Graham, B., and Levine, M. M., Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli, Lancet Infect Dis, vol. 16, no. 1, pp. 31-42, 2016.
2017
S. Joseph, Quinn, K., Greenwood, A., Cope, A. V., McKay, P. F., Hayes, P. J., Kopycinski, J. T., Gilmour, J., Miller, A. N., Geldmacher, C., Nadai, Y., Ahmed, M. I. M., Montefiori, D. C., Dally, L., Bouliotis, G., Lewis, D. J. M., Tatoud, R., Wagner, R., Esteban, M., Shattock, R. J., McCormack, S., and Weber, J., A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes., Front Immunol, vol. 8, p. 149, 2017.
T. Ford, Wenden, C., Mbekeani, A., Dally, L., Cox, J. H., Morin, M., Winstone, N., Hill, A. V. S., Gilmour, J., and Ewer, K. J., Cryopreservation-related loss of antigen-specific IFNγ producing CD4 T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy., Vaccine, vol. 35, no. 15, pp. 1898-1906, 2017.
J. Nyombayire, Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C. L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J. - L., Fast, P., Laufer, D. S., and Cox, J. H., First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens., J Infect Dis, vol. 215, no. 1, pp. 95-104, 2017.
M. J. Groome, Koen, A., Fix, A., Page, N., Jose, L., Madhi, S. A., McNeal, M., Dally, L., Cho, I., Power, M., Flores, J., and Cryz, S., Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial., Lancet Infect Dis, vol. 17, no. 8, pp. 843-853, 2017.